CERo Therapeutics
CERO
CERO was delisted on the 30th of October, 2025.
11 hedge funds and large institutions have $557K invested in CERo Therapeutics in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
57% more funds holding
Funds holding: 7 → 11 (+4)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
88% less capital invested
Capital invested by funds: $4.82M → $557K (-$4.26M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Arena Investors
Purchase,
New York
|
+$230K |
| 2 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$92.9K |
| 3 |
FLC
Fifth Lane Capital
Austin,
Texas
|
+$88.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$44.1K |
| 5 |
Two Sigma Investments
New York
|
+$20.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HH
HSG Holding
Na,
Hong Kong
|
-$202K |
| 2 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
-$30.7K |
| 3 |
FIA
FNY Investment Advisers
New York
|
-$4.64K |
CERO Hedge Fund Activity: Q2 2024 in Review
11 of the 6,927 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q2 2024, worth a combined $557K — down 88% from $4.82M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CERO positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Arena Investors, opening a new position worth an estimated $230K. The largest seller was HSG Holding, exiting entirely with an estimated $202K sold.
- 11 institutional investors held CERo Therapeutics (CERO) as of Q2 2024, up from 7 in Q1 2024.
- Funds reported $557K of CERo Therapeutics stock for Q2 2024, down 88% quarter-over-quarter.
- 6 funds opened new CERo Therapeutics positions in Q2 2024 and 2 closed out, a net change of +4 holders.
- The largest CERo Therapeutics buyer in Q2 2024 was Arena Investors, an estimated $230K added.
- The largest CERo Therapeutics seller in Q2 2024 was HSG Holding, an estimated $202K sold.
Based on aggregated 13F filings for Q2 2024.